AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Kintsugi 440mg Injection

Prescription Icon
Prescription Required

Marketer

Mankind Pharma Ltd

Salt Composition

Trastuzumab (440mg)

Overview Kintsugi 440mg Injection

Herceptin-equivalent injection (440mg) is indicated for managing breast and gastric cancers. Its mechanism involves targeted cell death via HER2 receptor inhibition. Administration is strictly intravenous, performed by a healthcare professional. Dosage and frequency are individually determined by your physician, varying based on treatment needs and potentially adjusted over time. Adhere precisely to the prescribed regimen; deviations can lead to severe adverse reactions. Therapeutic effects may take weeks or months to manifest; discontinue only under physician supervision. Common side effects encompass nausea, headache, skin rashes, sleep disturbances, and infections. Leukopenia and thrombocytopenia are potential risks, increasing infection vulnerability. Regular monitoring of blood counts, cardiac function, hepatic status, and uric acid levels is essential. Report immediately any shortness of breath, cough, chills, or limb edema. Inform your medical team of all concomitant medications, as interactions may occur. This treatment is contraindicated during pregnancy and lactation; reliable contraception for both partners is crucial throughout the treatment period.

Uses of Kintsugi 440mg Injection

Cancers affecting the breast and stomach

Major Benefits of Kintsugi 440mg Injection:

This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.

Common Side effects of Kintsugi 440mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Kintsugi 440mg Injection:

This medication will be administered by your physician or their qualified staff. Self-medication is strongly discouraged.

How Kintsugi 440mg Injection works:

Kintsugi 440mg Injection, a recombinant IgG1 monoclonal antibody, targets HER2 (human epidermal growth factor receptor 2) receptors. By binding to these receptors, prevalent in breast and gastric cancers, it prevents excessive cancer cell growth. This action directly destroys cancer cells and simultaneously disrupts multiple downstream signaling pathways implicated in cancer development.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of Kintsugi 440mg Injection and alcohol may result in pronounced somnolence.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Kintsugi 440mg Injection during pregnancy poses a confirmed risk to fetal development and is therefore contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The administration of Kintsugi 440mg Injection while breastfeeding is likely inadvisable. Available human data indicates a potential for the medication to transfer to breast milk, posing a risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The effect of Kintsugi 440mg Injection on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

Kintsugi 440mg Injection appears to be well-tolerated in individuals with impaired renal function. Preliminary findings indicate that dose modification for Kintsugi 440mg Injection may be unnecessary in this population. However, physician consultation is recommended.

LiverLiverCONSULT YOUR DOCTOR

Data regarding the administration of Kintsugi 440mg Injection to individuals with hepatic impairment is scarce. Physician consultation is advised.

What if you forget to take Kintsugi 440mg Injection :

Should you forget a scheduled dose of Kintsugi 440mg Injection, seek your physician's advice.

Facts to Know About Kintsugi 440mg Injection

LabelValue
Chemical Classification Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Medications
Actions Monoclonal antibody HER2/neu (ErbB2) inhibitor

FAQs on Kintsugi 440mg Injection

Kintsugi 440mg Injection may cause various side effects, including sore throat, fever, chills, fatigue, pale skin, nosebleeds, unusual bruising or bleeding, stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea, vomiting, loss of appetite, rapid heartbeat, discolored or decreased urine output, painful urination, and other signs of infection. Contact your doctor immediately if you experience any of these symptoms.
Effective contraception is recommended for women of childbearing age throughout Kintsugi 440mg Injection therapy and for seven months afterward. Pregnancy planning can resume seven months post-treatment.
Treatment with Kintsugi 440mg Injection should continue for one year in early-stage breast cancer patients, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Kintsugi 440mg Injection does not require fasting before administration. It must be administered by a qualified healthcare professional, under the supervision of a doctor experienced in cancer chemotherapy.
Kintsugi 440mg Injection is available in two formulations: intravenous (IV) infusion and subcutaneous injection. Always verify the correct formulation is used as prescribed, checking the product label. The IV formulation is for intravenous use only; it must not be given subcutaneously. Your doctor may change your treatment between IV and subcutaneous Kintsugi 440mg Injection if clinically appropriate.
Kintsugi 440mg Injection, a monoclonal antibody targeting the HER2 protein, is contraindicated in patients with HER2-negative cancer. Its mechanism of action relies on binding to HER2 receptors on cancer cells, inhibiting their growth and spread. Consequently, it's only effective in HER2-positive cancers where the HER2 protein is present.
Using Kintsugi 440mg Injection alongside anthracycline cancer drugs (like doxorubicin) can harm your heart. Therefore, your doctor must assess your heart health before and during treatment.
Cardiac evaluations should commence at treatment initiation, recurring every three months during treatment and every six months post-treatment for up to two years following the final Kintsugi 440mg Injection. Patients with pre-existing cardiac conditions require evaluation every twelve weeks.
Kintsugi 440mg Injection
21,128
MRP 24,515
13% off